Does hepatic dysfunction impair LDL clearance and worsen atherogenic lipoprotein profiles?

The liver is the central metabolic engine regulating systemic cholesterol homeostasis, acting as the primary anatomical clearance site for circulating lipoproteins.

Hepatic lipoprotein clearance

• The liver is responsible for approximately 80% of all LDL receptor (LDLR)-mediated uptake of low-density lipoproteins (LDL) from plasma, which translates to roughly two-thirds of total systemic LDL clearance.
• Hepatic LDLR clearance is the primary mechanism processing apolipoprotein B (apoB)-containing particles—including LDL, very-low-density lipoprotein (VLDL) remnants, and intermediate-density lipoproteins (IDL)—principally through high-affinity interactions with apoB100 and apolipoprotein E (apoE).

Mechanistic pathways of hepatic dysfunction

• In metabolic liver diseases such as non-alcoholic fatty liver disease (NAFLD), lipotoxic and inflammatory stress drives the upregulation of the transcription factor SREBP-2 and triggers de novo synthesis of proprotein convertase subtilisin/kexin type 9 (PCSK9).
• Elevated circulating and hepatic PCSK9 binds directly to cell-surface LDLR on hepatocytes, targeting these receptors for lysosomal degradation rather than recycling, which drastically reduces functional receptor availability.

Atherogenic lipid accumulation

• The loss of functional hepatic LDLR directly halts the clearance of circulating apoB-containing lipoproteins, causing systemic accumulation of these particles.
• This clearance defect, combined with insulin resistance-driven hepatic VLDL overproduction, shifts the plasma profile toward elevated apoB, high triglycerides, and a prominence of highly atherogenic small, dense, and oxidized LDL subfractions.

Bottom line

• Hepatic dysfunction directly impairs systemic LDL clearance by driving PCSK9-mediated degradation of hepatic LDL receptors, resulting in the systemic accumulation of atherogenic apoB-containing particles and worsening cardiovascular risk profiles.